---
import BaseLayout from '../layouts/BaseLayout.astro';
import { Icon } from 'astro-icon/components';
---

<BaseLayout title="SAR-001 - ASPSCR1-TFE3 Degrader" description="SAR-001 is a selective degrader targeting the ASPSCR1-TFE3 fusion protein for Alveolar Soft Part Sarcoma.">
  <Fragment slot="head">
    <link href="https://fonts.googleapis.com" rel="preconnect"/>
    <link crossorigin="" href="https://fonts.gstatic.com" rel="preconnect"/>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700;800&display=swap" rel="stylesheet"/>
  </Fragment>

  <!-- Fixed Background Layer -->
  <div class="fixed inset-0 z-0 pointer-events-none bg-ref-bg-light dark:bg-ref-bg-dark transition-colors duration-300">
      <div class="absolute inset-0 bg-[linear-gradient(to_right,#80808012_1px,transparent_1px),linear-gradient(to_bottom,#80808012_1px,transparent_1px)] bg-[size:24px_24px]"></div>
      <div class="absolute left-0 right-0 top-0 -z-10 m-auto h-[500px] w-[500px] rounded-full bg-purple-500/20 opacity-50 blur-[100px]"></div>
  </div>

  <!-- Scrollable Content Layer -->
  <div class="relative z-10 text-slate-800 dark:text-slate-200 font-sans">
    
    <!-- Header Section -->
    <header class="relative pt-6 pb-16 w-full">
        <div class="max-w-[90%] mx-auto px-4 sm:px-6 lg:px-8 text-center">
            <h1 class="text-4xl md:text-6xl font-extrabold text-slate-900 dark:text-white tracking-tight mb-6 leading-tight">
                SAR-001 <br class="hidden md:block"/>
                <span class="text-transparent bg-clip-text bg-gradient-to-r from-ref-primary to-indigo-600 dark:from-purple-400 dark:to-indigo-400">
                    Selective Degrader
                </span>
            </h1>
            <p class="max-w-3xl mx-auto text-lg md:text-xl text-slate-600 dark:text-slate-400 leading-relaxed">
                A precision therapeutic targeting the ASPSCR1-TFE3 fusion driver in Alveolar Soft Part Sarcoma.
            </p>
        </div>
    </header>

    <main class="max-w-[85%] mx-auto px-4 sm:px-6 lg:px-8 pb-24 space-y-16">
        
        <!-- The Target -->
        <section class="relative group">
            <div class="absolute -inset-4 bg-gradient-to-r from-purple-50 to-indigo-50 dark:from-slate-800/50 dark:to-slate-900/50 rounded-[2.5rem] -z-10 opacity-50 blur-xl transition duration-500 group-hover:opacity-100"></div>
            <div class="bg-ref-surface-light dark:bg-ref-surface-dark rounded-2xl p-8 md:p-12 shadow-xl border border-slate-200 dark:border-slate-700">
                <div class="flex flex-col md:flex-row gap-12 items-center">
                    <div class="flex-1">
                        <div class="flex items-center gap-3 mb-4">
                            <div class="p-2 bg-purple-100 dark:bg-purple-900/50 rounded-lg text-ref-primary">
                                <Icon name="mdi:target" class="w-6 h-6" />
                            </div>
                            <h2 class="text-2xl font-bold text-slate-900 dark:text-white">The Target</h2>
                        </div>
                        <h3 class="text-xl font-semibold text-ref-primary mb-4">ASPSCR1-TFE3 Fusion</h3>
                        <p class="text-slate-600 dark:text-slate-300 mb-6 leading-relaxed">
                            Alveolar Soft Part Sarcoma (ASPS) is driven by a single, defining molecular event: the t(X;17)(p11;q25) translocation. This creates the <strong>ASPSCR1-TFE3</strong> fusion protein, a constitutively active transcription factor that drives tumor growth, angiogenesis, and immune evasion.
                        </p>
                        <p class="text-slate-600 dark:text-slate-300 leading-relaxed">
                            Unlike other cancers with complex mutational landscapes, ASPS is addicted to this single driver, making it an ideal candidate for precision targeting.
                        </p>
                    </div>
                    <div class="w-full md:w-1/3 flex justify-center">
                         <div class="p-6 bg-slate-50 dark:bg-slate-900 rounded-xl border border-slate-100 dark:border-slate-700 text-center">
                            <div class="text-6xl font-black text-slate-200 dark:text-slate-800 mb-2">TFE3</div>
                            <div class="text-sm font-bold text-slate-500 uppercase tracking-wider">Oncogenic Driver</div>
                         </div>
                    </div>
                </div>
            </div>
        </section>

        <!-- The Modality -->
        <section class="grid md:grid-cols-2 gap-8">
            <div class="bg-white dark:bg-slate-800 rounded-2xl p-8 shadow-lg border border-slate-200 dark:border-slate-700">
                <div class="flex items-center gap-3 mb-6">
                    <div class="p-2 bg-blue-100 dark:bg-blue-900/30 rounded-lg text-blue-600">
                        <Icon name="mdi:molecule" class="w-6 h-6" />
                    </div>
                    <h2 class="text-2xl font-bold text-slate-900 dark:text-white">The Modality</h2>
                </div>
                <h3 class="text-lg font-semibold text-slate-800 dark:text-slate-200 mb-3">Targeted Protein Degradation (PROTACs)</h3>
                <p class="text-slate-600 dark:text-slate-300 leading-relaxed mb-4">
                    Traditional inhibitors often fail to block transcription factors like TFE3 because they lack deep binding pockets. SAR-001 utilizes <strong>Targeted Protein Degradation</strong>.
                </p>
                <p class="text-slate-600 dark:text-slate-300 leading-relaxed">
                    Instead of just blocking the protein, SAR-001 recruits the cell's own waste disposal system (the ubiquitin-proteasome system) to physically destroy the ASPSCR1-TFE3 protein, removing the driver of the disease entirely.
                </p>
            </div>

            <div class="bg-white dark:bg-slate-800 rounded-2xl p-8 shadow-lg border border-slate-200 dark:border-slate-700">
                <div class="flex items-center gap-3 mb-6">
                    <div class="p-2 bg-emerald-100 dark:bg-emerald-900/30 rounded-lg text-emerald-600">
                        <Icon name="mdi:chart-line" class="w-6 h-6" />
                    </div>
                    <h2 class="text-2xl font-bold text-slate-900 dark:text-white">Differentiation</h2>
                </div>
                <div class="space-y-6">
                    <div>
                        <h4 class="font-bold text-red-500 mb-1">VCP Inhibition (e.g., CB-5083)</h4>
                        <p class="text-sm text-slate-600 dark:text-slate-400">Broad mechanism. High systemic toxicity. Failed in clinic due to off-target effects (visual disturbances).</p>
                    </div>
                    <div class="w-full h-px bg-slate-100 dark:bg-slate-700"></div>
                    <div>
                        <h4 class="font-bold text-emerald-500 mb-1">SAR-001 Degradation</h4>
                        <p class="text-sm text-slate-600 dark:text-slate-400">Selective precision. Targets only the fusion protein. Designed to spare wild-type TFE3 and minimize systemic toxicity.</p>
                    </div>
                </div>
            </div>
        </section>

        <!-- Unmet Need -->
        <section class="bg-ref-surface-light dark:bg-ref-surface-dark rounded-2xl p-8 md:p-12 shadow-xl border border-slate-200 dark:border-slate-700">
            <div class="flex items-center gap-3 mb-6">
                <div class="p-2 bg-orange-100 dark:bg-orange-900/30 rounded-lg text-orange-600">
                    <Icon name="mdi:alert-circle" class="w-6 h-6" />
                </div>
                <h2 class="text-2xl font-bold text-slate-900 dark:text-white">The Unmet Need</h2>
            </div>
            <div class="grid md:grid-cols-2 gap-8">
                <div>
                    <h3 class="text-lg font-semibold text-slate-800 dark:text-slate-200 mb-2">Current Standard of Care</h3>
                    <p class="text-slate-600 dark:text-slate-300 leading-relaxed">
                        Patients currently rely on <strong>Atezolizumab</strong> (immunotherapy) and TKIs. While these can stabilize disease, they are rarely curative and response rates vary. There is no approved therapy targeting the underlying genetic driver.
                    </p>
                </div>
                <div>
                    <h3 class="text-lg font-semibold text-slate-800 dark:text-slate-200 mb-2">Previous Failures</h3>
                    <p class="text-slate-600 dark:text-slate-300 leading-relaxed">
                        Previous attempts to target the pathway via VCP inhibitors (like CB-5083) failed due to unacceptable toxicity. A more precise approach is required.
                    </p>
                </div>
            </div>
        </section>

        <!-- Development Status removed per request -->

    </main>
  </div>
</BaseLayout>
